GlassScriptPhysician profile
Rajesh Agarwal
NPI 1285618579
$7,233.26
in general payments reported to CMS, 2019-2025
44 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $315 · 2021: $57.66 · 2022: $540 · 2023: $1,088 · 2024: $860 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,946 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.63 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,392.31 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Pfizer INC. | $689.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $687.78 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $583.82 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $474.19 | 2019-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $472.94 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $346.11 | 2019-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $264.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.19 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $175.06 | 2019-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $162.22 | 2019-2020 | |
| Abbvie INC. | $151.20 | 2019-2025 | Qulipta, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $150.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $147.76 | 2019-2025 | Austedo Xr |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.